Alkermes rises after narcolepsy drug shows promise in mid-stage study

Alkermes

21/07/2025 12:22

** Shares of drugmaker Alkermes ALKS.O up 1.8% at $29.75 premarket

** Company says its experimental drug, alixorexton, showed clinically meaningful and statistically significant improvements in wakefulness at all doses, compared to placebo, in patients with narcolepsy type-1 in a mid-stage study

** Narcolepsy is a chronic neurological disorder that disrupts the body's ability to regulate sleep-wake cycles

** ALKS says alixorexton was generally well tolerated at all doses tested

** Alkermes says the drug showed "robust and clinically meaningful improvements compared to placebo on patient-reported outcomes related to excessive daytime sleepiness and other key symptoms such as fatigue and cognition"

** As of last close, stock up 1.6% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))